Semaglutide Cuts Incidence, Recurrence of Alcohol Use Disorder
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
TUESDAY, June 25, 2024 -- Semaglutide may cut incidence and recurrence of alcohol use disorder (AUD) in patients with obesity, according to a study published online May 28 in Nature Communications.
William Wang, from Case Western Reserve University in Cleveland, and colleagues used electronic health records of 83,825 patients with obesity to examine associations between AUD and semaglutide use.
The researchers found that compared with other antiobesity medications, semaglutide was associated with a 50 to 56 percent lower risk for both the incidence and recurrence of AUD over a 12-month follow-up period. Across gender, age group, race, and in patients with and without type 2 diabetes (T2DM), similar associations were seen. An additional study population of 598,803 patients with T2DM showed similar results.
"In summary, our results find an association between reduced risk for incident and AUD relapse with the prescription of semaglutide in patients with obesity or T2DM," the authors write. "While these findings provide preliminary evidence of the potential benefit of semaglutide in AUD in real-world populations further randomized clinical trials are needed to support its use clinically for AUD."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-06-26 01:15
Read more
- FDA Grants Rare Pediatric Disease Designation to Omeros’ MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy
- Vitamin D Supplements Could Help Lower Blood Pressure in Obese People
- July 2019 to June 2023 Saw Increase in OD Deaths With Ketamine Detected
- Diabetes, High BMI, Previous Metformin Common in Teens With Rx for GLP-1 RAs
- Seniors Who Split: Rates of 'Gray Divorce' Have Tripled Since 1990
- Female Pediatricians Earn About 93 Percent of Male Pediatricians
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions